Why the study?
Does CYP2C19 genotype-directed antiplatelet therapy improve outcomes in clopidogrel-treated patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Population
Patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI)
Design
Guideline
Authors
Loading...
Refines CYP2C19-guided antiplatelet indications in ACS/PCI; extends prior CPIC guidelines with allele-specific refinements from expanded evidence.
Does CYP2C19 genotype-directed antiplatelet therapy improve outcomes in clopidogrel-treated patients with acute coronary syndromes undergoing percutaneous coronary intervention?
The 2013 CPIC guideline update provides refined recommendations for CYP2C19 genotype-directed antiplatelet therapy to reduce adverse cardiovascular events in clopidogrel-treated patients with ACS undergoing PCI.
Scott et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: